Literature DB >> 11109000

Spatial memory and learning deficits after experimental pneumococcal meningitis in mice.

A Wellmer1, C Noeske, J Gerber, U Munzel, R Nau.   

Abstract

Survivors of bacterial meningitis frequently suffer from long-term sequelae, particularly from learning and memory deficits. For this reason, spatial memory and learning was studied in a mouse model of ceftriaxone-treated Streptococcus pneumoniae meningitis. Persistent deficits of spatial learning despite normal motor function were observed in mice infected with 10(4) colony-forming units (CFU) in 25 microl of saline into the right forebrain in comparison to mice treated with an equal amount of saline. Survivors of meningitis performed significantly worse in memorizing a hidden platform in a Morris water maze. After 2 weeks, the difference between post-meningitis and control mice diminished. Yet, when the platform was moved after 180 days, learning of the new location was still strongly impaired in mice surviving meningitis.

Entities:  

Mesh:

Year:  2000        PMID: 11109000     DOI: 10.1016/s0304-3940(00)01645-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  Experimental pneumococcal meningitis: impaired clearance of bacteria from the blood due to increased apoptosis in the spleen in Bcl-2-deficient mice.

Authors:  Andreas Wellmer; Matthias von Mering; Annette Spreer; Ricarda Diem; Helmut Eiffert; Christiane Noeske; Stefanie Bunkowski; Ralf Gold; Roland Nau
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis.

Authors:  Marija Djukic; Tobias Böttcher; Andreas Wellmer; Joachim Gerber; Viola V Brocke; Helmut Eiffert; Roland Nau
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response.

Authors:  Jagath L Kadurugamuwa; Kshitij Modi; Olivier Coquoz; Brad Rice; Steven Smith; Pamela R Contag; Tony Purchio
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 4.  Inflammation in neurodegenerative diseases.

Authors:  Sandra Amor; Fabiola Puentes; David Baker; Paul van der Valk
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

5.  Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis.

Authors:  Andreas Wellmer; Gregor Zysk; Joachim Gerber; Tammo Kunst; Matthias Von Mering; Stefanie Bunkowski; Helmut Eiffert; Roland Nau
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Dexamethasone decreases neurological sequelae and caspase activity.

Authors:  Jose Irazuzta; Robert K Pretzlaff; Gabrielle DeCourten-Myers; Frank Zemlan; Basilia Zingarelli
Journal:  Intensive Care Med       Date:  2004-10-16       Impact factor: 17.440

7.  Time-dependent behavioral recovery after pneumococcal meningitis in rats.

Authors:  Tatiana Barichello; Geruza Z Silva; Jaqueline S Generoso; Geovana D Savi; Cleonice M Michelon; Gustavo Feier; Clarissa M Comim; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2010-06-18       Impact factor: 3.575

Review 8.  The role of pneumolysin in pneumococcal pneumonia and meningitis.

Authors:  R A Hirst; A Kadioglu; C O'callaghan; P W Andrew
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

Review 9.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway.

Authors:  Zheng Li; Qian-Qian Ma; Yan Yan; Feng-Dan Xu; Xiao-Ying Zhang; Wei-Qin Zhou; Zhi-Chun Feng
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.